Developing a new MRI contrast agent to improve prostate cancer diagnosis
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
This study is testing a new MRI contrast agent that helps doctors tell the difference between aggressive and less serious prostate cancer, so patients can get the right treatment without unnecessary procedures.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Theranostics, LLC NIH-funded |
| Lab location | 1 site (Beachwood, United States) |
| Project ID | NIH-10704488 on NIH RePORTER |
What this research studies
This research focuses on creating a novel MRI contrast agent designed to enhance the differentiation between high-risk and low-risk prostate cancer. By targeting specific oncoproteins associated with aggressive cancer characteristics, the study aims to provide a more accurate imaging tool that can help physicians make better treatment decisions. Patients will benefit from a non-invasive method that could reduce unnecessary treatments for those with low-risk cancer. The approach involves optimizing and commercializing the contrast agent MT218 for improved early detection and localization of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who are at risk of having high-grade tumors.
Not a fit: Patients with benign prostate conditions or those with very low-risk prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses of prostate cancer, allowing for tailored treatment plans that spare patients from unnecessary aggressive therapies.
How similar studies have performed: Previous research has shown promise in using targeted imaging agents for cancer diagnosis, indicating potential success for this novel approach.
Where this research is happening
Beachwood, United States
- Molecular Theranostics, LLC — Beachwood, United States (Active)
Researchers
- Principal investigator: Gao, Songqi — Molecular Theranostics, LLC
- Study coordinator: Gao, Songqi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.